Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jun 17;11(6):e0157417.
doi: 10.1371/journal.pone.0157417. eCollection 2016.

Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis

Affiliations
Meta-Analysis

Association of Vasomotor and Other Menopausal Symptoms with Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis

Taulant Muka et al. PLoS One. .

Abstract

Importance: Vasomotor symptoms (hot flushes and night sweats) and other symptoms, including depression, anxiety and panic attacks, are commonly experienced by menopausal women and have been associated with an unfavourable cardiovascular risk profile.

Objective: To investigate whether presence of menopausal symptoms is associated with the development of cardiovascular disease (CVD).

Methods: Five electronic databases (Medline, EMBASE and Web of Science) were search until February 17th, 2015 to identify relevant studies. Observational cohort studies or randomised intervention studies were eligible for inclusion if they followed participants prospectively (at least 1 year of follow-up), and reported relevant estimates on the association of any vasomotor symptoms, or other menopausal symptoms, with risk of CVD, coronary heart disease (CHD), or stroke in perimenopausal, menopausal, or postmenopausal women. Data were extracted by two independent reviewers using a pre-designed data collection form. Separate pooled relative risks (RRs) for age and non-established cardiovascular risk factors (e.g., education, ethnicity) adjusted data and for established cardiovascular risk factors and potential mediators-adjusted data (e.g., smoking, body mass index, and hypertension) were calculated.

Results: Out of 9,987 initially identified references, ten studies were selected, including 213,976 women with a total of 10,037 cardiovascular disease outcomes. The age and non-established cardiovascular risk factors adjusted RRs) [95% confidence intervals] for development of CHD, Stroke and CVD comparing women with and without any menopausal symptoms were 1.34 [1.13-1.58], 1.30 [0.99-1.70], 1.48 [1.21-1.80] respectively, and the corresponding RRs adjusted for cardiovascular risk factors and potential mediators were 1.18 [1.03-1.35], 1.08 [0.89-1.32], 1.29 [0.98-1.71]. However, these analyses were limited by potential unmeasured confounding and the small number of studies on this topic.

Conclusion: Presence of vasomotor symptoms and other menopausal symptoms are generally associated with an increased risk of cardiovascular disease, which is mainly explained by cardiovascular risk factors.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: TM and OHF work in ErasmusAGE, a xenter for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. MK is supported by the AXA Research Fund. Nestlé Nutrition (Nestec Ltd.), Metagenics Inc. AXA had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review or approval of the manuscript. There are no patents, products in development or marketed products to declare. This did not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Flow diagram of studies included in the current review.
Fig 2
Fig 2. Relative risks of coronary heart disease associated with menopausal symptoms.
Basic model: adjusted for age and non-established cardiovascular risk factors; Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms; vasomotor symptoms include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal symptoms such as depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 7 = 81.22, I2 = 91%, 85 to 95%; P < 0.001; vasomotor symptoms, X2 1 = 1.55, I2 = 35%; P = 0.213; other symptoms, X2 5 = 63.48, I2 = 92%, 86 to 96%; P < 0.001. Assessment of heterogeneity for fully-adjusted model: All symptoms, X2 6 = 29.20, I2 = 79%, 58 to 90%; P < 0.001; vasomotor symptoms, X2 1 = 0.09, I2 = 0%; P = 0.762; other symptoms, X2 4 = 22.63, I2 = 82%, 59 to 92%; P < 0.001.
Fig 3
Fig 3. Relative risks of stroke associated with menopausal symptoms.
Basic model: adjusted for age and non-established cardiovascular risk factors; Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms; vasomotor symptoms include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal symptoms such as depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 2 = 3.26, I2 = 39%, 0 to 81%; P = 0.196; other symptoms, X2 1 = 2.03, I2 = 51%, 0 to 87%; P = 0.154. Assessment of heterogeneity for full-adjusted model: All symptoms, X2 2 = 1.86, I2 = 0%, 0 to 90%; P = 0.395; other symptoms, X2 1 = 1.72, I2 = 42%; P = 0.189.
Fig 4
Fig 4. Relative risks of cardiovascular disease associated with menopausal symptoms.
Basic model: adjusted for age and non-established cardiovascular risk factors; Fully-adjusted model, adjusted for established cardiovascular risk factors and potential mediators. VMS, vasomotor symptoms; vasomotor symptoms include hot flashes and /or night sweats; All, includes vasomotor and other menopausal symptoms; Other, includes menopausal symptoms such as depression, insomnia, and panic attacks. Assessment of heterogeneity for basic model: All symptoms, X2 3 = 9.95, I2 = 70%, 13 to 90%; P = 0.019; other symptoms, X2 2 = 7.05, I2 = 72%, 4 to 92%; P = 0.045. Assessment of heterogeneity for full-adjusted model: All symptoms, X2 3 = 8.68, I2 = 65%, 0 to 88%; P = 0.034; other symptoms, X2 2 = 8.67, I2 = 77%, 25 to 93%; P = 0.013.

Similar articles

Cited by

References

    1. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96(3):351–8. Epub 2000/08/29. doi: S0029-7844(00)00930-3 [pii]. . - PubMed
    1. Dibonaventura MD, Chandran A, Hsu MA, Bushmakin A. Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Womens Health. 2013;5:261–9. Epub 2013/06/06. 10.2147/IJWH.S39027 ijwh-5-261 [pii]. - DOI - PMC - PubMed
    1. Reed SD, Lampe JW, Qu C, Gundersen G, Fuller S, Copeland WK, et al. Self-reported menopausal symptoms in a racially diverse population and soy food consumption. Maturitas. 2013;75(2):152–8. Epub 2013/04/09. doi: S0378-5122(13)00060-1 [pii] 10.1016/j.maturitas.2013.03.003 . - DOI - PubMed
    1. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med. 2006;166(12):1262–8. Epub 2006/06/28. doi: 166/12/1262 [pii] 10.1001/archinte.166.12.1262 . - DOI - PubMed
    1. Thurston RC, Blumenthal JA, Babyak MA, Sherwood A. Association between hot flashes, sleep complaints, and psychological functioning among healthy menopausal women. Int J Behav Med. 2006;13(2):163–72. 10.1207/s15327558ijbm1302_8 ISI:000238435200008. - DOI - PubMed